GlassScriptPhysician profile
Marta J Wayt
NPI 1316903099
$2,963.74
in general payments reported to CMS, 2019-2025
39 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $626 · 2021: $642 · 2022: $143 · 2023: $196 · 2024: $171 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $762.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $455.50 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $286.26 | 2019-2023 | Vraylar |
| Pfizer INC. | $132.13 | 2019-2023 | |
| Exact Sciences Corporation | $86.40 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $84.23 | 2019-2022 | |
| Astellas Pharma US INC | $80.01 | 2019-2025 | Veozah |
| Lilly USA, LLC | $79.20 | 2019-2023 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $72.87 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $69.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $66.25 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $61.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $61.18 | 2019-2021 | |
| Abbott Laboratories | $60.18 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.06 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Wayt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.